HK Stock Market Move | 3SBIO(01530) surges over 9% in the afternoon, domestic approval for SSGJ-707 for clinical use in lung cancer and kidney cancer.

3SBIO (01530) rose more than 9% in the afternoon, up 7.2% to HK$24.7 as of the time of writing, with a turnover of HK$1.303 billion. On the news front, on April 7th, the CDE official website showed that Pfizer's category 1 new drug PF-08634404 (3SBIO research and development code: SSGJ-707) has officially received approval for two major indications in clinical trials: first-line treatment of transformational small cell lung cancer in combination with chemotherapy, and monotherapy / combination therapy for localized advanced or metastatic renal cell carcinoma. Public information shows that SSGJ-707 is a PD-1/VEGF dual antibody developed by 3SBIO. In May 2025, Pfizer introduced the product's global development and commercialization rights for over $6 billion, including a $1.4 billion upfront payment and $100 million in equity cooperation, breaking the record for the upfront payment in a single out-licensing deal for innovative drugs in China. Leveraging Pfizer's clinical resources, the clinical progress of SSGJ-707 is advancing efficiently, with three Phase III clinical trials already underway for indications including colorectal cancer and non-small cell lung cancer, and planned Phase III clinical trial indications including endometrial cancer and urothelial carcinoma.